Skip to main content

Funding Opportunities and Announcements

Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3 Clinical Trial Optional)


Funding opportunities for the Transformative Research to Address Health Disparities and Advance Health Equity initiative - read the article about these two funding opportunities here. Below are the two listings:


Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)


Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional)


Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)


Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional)


Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed).


New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial Required)


Four New Funding Opportunities, Rapid Acceleration of Diagnostics (RADX) Related to COVID-19 Testing


Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional)  



Advancing HIV/AIDS Research within the Mission of the NIDCD (two opportunities), standard AIDS dates apply. Expires in 2023.

R21 Clinical Trial Optional

R01 Clinical Trial Optional


Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities


NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)


Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 No Independent Clinical Trials)


Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)


Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed)